Table 3.
Univariate and multivariate analysis of prognostic factors for cause-specific mortality among patients with T1–2N0M0 breast cancer.
| Overall mortality | Breast cancer-specific mortality | CVD mortality | ||||
| Variable | HR1 (95% CI) | Adj HR1 (95% CI) | HR1 (95% CI) | Adj HR1 (95% CI) | HR1 (95% CI) | Adj HR1 (95% CI) |
| Age, y | ||||||
| ≤45 | Ref | Ref | Ref | Ref | Ref | Ref |
| 45–65 | 1.019 (0.921–1.126) | 1.206 (1.090–1.334) | 0.637 (0.566–0.717) | 0.910 (0.808–1.025) | 4.097 (2.296–7.312) | 4.426 (2.479–7.901) |
| 65–85 | 3.163 (2.875–3.480) | 4.057 (3.683–4.469) | 0.953 (0.848–1.071) | 1.685 (1.496–1.897) | 29.660 (16.803–52.357) | 33.176 (18.779–58.612) |
| >85 | 15.175 (13.719–16.785) | 18.057 (16.306–1.995) | 3.587 (3.117–4.128) | 5.644 (4.893–6.511) | 198.926 (112.470–351.841) | 209.943 (118.591–371.666) |
| Race | ||||||
| White | Ref | Ref | Ref | Ref | Ref | Ref |
| Black | 1.270 (1.198–1.347) | 1.320 (1.245–1.401) | 1.867 (1.703–2.046) | 1.442 (1.314–1.584) | 1.027 (0.900–1.173) | 1.273 (1.114–1.456) |
| Other | 0.553 (0.507–0.603) | 0.652 (0.598–0.710) | 0.647 (0.557–0.750) | 0.654 (0.563–0.759) | 0.531 (0.443–0.637) | 0.709 (0.591–0.851) |
| Grade | ||||||
| Well | Ref | Ref | Ref | Ref | Ref | Ref |
| Moderately | 1.211 (1.152–1.272) | 1.114 (1.060–1.172) | 2.390 (2.100–2.720) | 1.988 (1.745–2.265) | 1.056 (0.961–1.161) | 0.989 (0.898–1.089) |
| Poorly | 1.691 (1.607–1.780) | 1.472 (1.386–1.563) | 7.099 (6.277–8.029) | 3.998 (3.491–4.579) | 0.906 (0.812–1.012) | 0.923 (0.812–1.050) |
| Undifferentiated | 2.088 (1.545–2.823) | 2.073 (1.531–2.807) | 10.077 (6.699–15.160) | 6.469 (4.283–9.771) | 0.502 (0.162–1.560) | 0.586 (0.188–1.825) |
| Molecular type | ||||||
| HR+/HER2− | Ref | Ref | Ref | Ref | Ref | Ref |
| HR+/HER2+ | 0.959 (0.893–1.030) | 1.016 (0.944–1.093) | 1.416 (1.250–1.604) | 0.999 (0.879–1.135) | 0.873 (0.751–1.014) | 1.215 (1.041–1.418) |
| HR−/HER2+ | 1.177 (1.062–1.304) | 1.137 (1.022–1.264) | 2.533 (2.183–2.939) | 1.454 (1.246–1.697) | 1.226 (1.086–1.358) | 1.391 (1.209–1.601) |
| HR−/HER2− | 1.785 (1.696–1.878) | 1.542 (1.454–1.635) | 4.354 (4.032–4.701) | 2.145 (1.962–2.345) | 1.439 (1.315–1.557) | 1.515 (1.213–1.892) |
| T stage | ||||||
| T1 | Ref | Ref | Ref | Ref | Ref | Ref |
| T2 | 2.127 (2.046–2.211) | 1.860 (1.786–1.937) | 4.018 (3.749–4.305) | 2.732 (2.542–2.936) | 1.697 (1.561–1.846) | 1.610 (1.475–1.757) |